According to Capricor Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.96581. At the end of 2022 the company had a P/E ratio of -3.27.
Year | P/E ratio | Change |
---|---|---|
2022 | -3.27 | -2.87% |
2021 | -3.37 | -7.7% |
2020 | -3.65 | 501.5% |
2019 | -0.6066 | -22.32% |
2018 | -0.7810 | -101.48% |
2017 | 52.7 | -2119.55% |
2016 | -2.61 | -31.19% |
2015 | -3.79 | -47.44% |
2014 | -7.21 | 90.83% |
2013 | -3.78 | 269.06% |
2012 | -1.02 | -75.8% |
2011 | -4.23 | 29.65% |
2010 | -3.26 | -16.4% |
2009 | -3.90 | 152.56% |
2008 | -1.55 | -83.7% |
2007 | -9.48 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 10.4 | -363.50% | ๐บ๐ธ USA |
![]() Neurocrine Biosciences
NBIX | 68.9 | -1,837.81% | ๐บ๐ธ USA |
![]() Cytokinetics
CYTK | -9.29 | 134.30% | ๐บ๐ธ USA |
![]() Celldex Therapeutics CLDX | -15.1 | 280.44% | ๐บ๐ธ USA |
![]() Palatin Technologies PTN | -0.6115 | -84.58% | ๐บ๐ธ USA |
![]() Eterna Therapeutics ERNA | -0.3226 | -91.86% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.